1. 1459PWhich of afatinib and gefitinib/erlotinib is the better EGFR-TKI to be followed by osimertinib?. (23rd October 2018) Authors: Tamiya, M; Tamiya, A; Suzuki, H; Nakahama, K; Taniguchi, Y; Kunimasa, K; Kimura, M; Inoue, T; Nishino, K; Hirashima, T; Atagi, S; Imamura, F; Kumagai, T Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 516PClinical outcomes in elderly patients with advanced non-small cell lung cancer: A prospective multicenter study of the National Hospital Organization in Japan. (24th November 2019) Authors: Shimada, M; Kanazu, M; Shimokawa, M; Saito, R; Mori, M; Tamura, A; Okano, Y; Fujita, Y; Endo, T; Motegi, M; Takata, S; Kita, T; Sukoh, N; Takenoyama, M; Atagi, S Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 534TiPA randomized phase III study of carboplatin plus nab-paclitaxel with or without nintedanib for NSCLC with IPF (J-SONIC). (24th November 2019) Authors: Otsubo, K; Kishimoto, J; Kenmotsu, H; Minegishi, Y; Horinouchi, H; Kato, T; Ichihara, E; Shiraki, A; Atagi, S; Ando, M; Yamamoto, N; Okamoto, I Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 79P Nivolumab treatment beyond progression disease in advanced non-small cell lung cancer. (15th December 2019) Authors: Enomoto, T; Tamiya, A; Matsumoto, K; Adachi, Y; Azuma, K; Inagaki, Y; Kouno, S; Taniguchi, Y; Saijo, N; Okishio, K; Atagi, S Journal: Annals of oncology Issue: Volume 30(2019)Supplement 11 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 83P Analysis of predictive factors in non-small cell lung cancer patients treated with nivolumab. (15th December 2019) Authors: Azuma, K; Tamiya, A; Adachi, Y; Enomoto, T; Kouno, S; Taniguchi, Y; Saijo, N; Okishio, K; Atagi, S Journal: Annals of oncology Issue: Volume 30(2019)Supplement 11 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Effect of pembrolizumab on patients harboring uncommon epidermal growth factor receptor mutations. (7th March 2018) Authors: Taniguchi, Y; Tamiya, A; Ishii, S; Atagi, S Journal: Annals of oncology Issue: Volume 29:Number 5(2018) Page Start: 1331 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer. (25th September 2019) Authors: Yoshioka, H; Shimokawa, M; Seto, T; Morita, S; Yatabe, Y; Okamoto, I; Tsurutani, J; Satouchi, M; Hirashima, T; Atagi, S; Shibata, K; Saito, H; Toyooka, S; Yamamoto, N; Nakagawa, K; Mitsudomi, T Journal: Annals of oncology Issue: Volume 30:Number 12(2019) Page Start: 1978 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Programmed death-ligand 1 expression in uncommon epidermal growth factor receptor mutation-positive non-small-cell lung cancer. (10th September 2018) Authors: Taniguchi, Y; Takeda, M; Tamiya, A; Kasai, T; Atagi, S Journal: Annals of oncology Issue: Volume 29:Number 11(2018) Page Start: 2262 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗